# Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer

> **NCT00096395** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 33 (actual)

## Conditions studied

- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** sorafenib tosylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00096395
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-02
- **Final completion:** —
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2013-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096395, "Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00096395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*